Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Chemomab Therapeutics Ltd fell by 4.23m. However, Cash Flow from Investing totalled 15.88m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 23.61m for operations while cash generated from financing totalled 3.50m.
Cash flow per share | -0.7085 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.6954 |
---|---|
Tangible book value per share | 0.6954 |
More ▼